Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO 35b olaparib beyond progression after secondary cytoreductive surgery in recurrent ovarian cancer
2024-516842-21-00Phase 3Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoints: progression-free survival and progression-free survival 2. Planned start Jan 2025; status: authorised.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-516842-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516842-21-00.